It was reported on Thursday that JanOne Inc (NASDAQ: JAN), a pharmaceutical company focused on pain reduction treatments, has begun a contract to manufacture TV1001SR, a treatment for Peripheral Artery Disease.
The product aims to address the underlying cause of Peripheral Artery Disease and associated pain, as a potential alternative to opioids.
Tony Giordano, PhD, JanOne's chief scientific officer, said, 'CoreRx's extensive clinical development experience and capabilities made them a natural choice for phase 2b formulation and manufacturing. As we finalize our clinical protocols for FDA submission and enter the next phase of trials for what we believe could be an effective PAD treatment, CoreRx is a proven partner with exceptional quality controls.'
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA